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Tick-borne encephalitis is usually caused by infection with one of two flaviviruses: Russian spring summer encephalitis
virus (RSSEV) or Central European encephalitis virus (CEEV). We previously demonstrated that gene gun inoculation of mice
with naked DNA vaccines expressing the prM and E genes of these viruses resulted in long-lived homologous and
heterologous protective immunity (Schmaljohn et al., 1997). To further evaluate these vaccines, we inoculated rhesus
macaques by gene gun with the RSSEV or CEEV vaccines or with both DNA vaccines and compared resulting antibody titers
with those obtained by vaccination with a commercial, formalin-inactivated vaccine administered at the human dose.
Vaccinations were given at days 0, 30, and 70. All of the vaccines elicited antibodies detected by ELISA and by plaque-
reduction neutralization tests. The neutralizing antibody responses persisted for at least 15 weeks after the final vaccination.
Because monkeys are not uniformly susceptible to tick-borne encephalitis, the protective properties of the vaccines were
assessed by passive transfer of monkey sera to mice and subsequent challenge of the mice with RSSEV or CEEV. One hour
after transfer, mice that received 50 ml of sera from monkeys vaccinated with both DNA vaccines had circulating neutralizing
antibody levels ,20–80. All of these mice were protected from challenge with RSSEV or CEEV. Mice that received 10 ml of
sera from monkeys vaccinated with the individual DNA vaccines, both DNA vaccines, or a commercial vaccine were partially
to completely protected from RSSEV or CEEV challenge. These data suggest that DNA vaccines may offer protective
immunity to primates similar to that obtained with a commercial inactivated-virus vaccine. © 1999 Academic Press
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Tick-borne encephalitis (TBE) is one of the most clin-
cally important arthropod-borne viral diseases in Europe
nd in the former Soviet Union. TBE occurs in all coun-
ries of Central and Eastern Europe, as well as in Scan-
inavia, France, Italy, Greece, and Albania (reviewed in
onath and Heinz, 1996). Two tick-borne flaviviruses,
ussian spring summer encephalitis virus (RSSEV) and
entral European encephalitis virus (CEEV), are the pri-
ary causes of TBE. The distribution of the viruses is
estricted by the range of their tick vectors: Ixodes per-
ulcatus for RSSEV and Ixodes ricinus for CEEV. Al-
hough RSSEV and CEEV are antigenically and geneti-
ally similar, with 96% amino acid sequence homology in
he envelope (E) proteins, RSSEV causes a more severe
isease than does CEEV. Infection with RSSEV has a
ase fatality rate of approximately 20%, and 30–60% of
urvivors show neurological sequelae, including paraly-
is of the shoulder girdle and arms. In contrast, TBE
aused by CEEV has a case fatality rate of 1–2%, and
1 Present address: U.S. Army Medical Research and Materiel Com-
and, Headquarters, SARD-TM, 2511 Jefferson Davis Highway, Suite
000, Arlington, VA 22202-3911.
2 To whom reprint requests should be addressed at 1425 Porter
treet. Fax: (301) 619-2439. E-mail: connie.schmaljohn@amedd.
trmy.mil.
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166erious neurological sequelae are rare (reviewed in
onath and Heinz, 1996).
The use of commercially available vaccines has nota-
ly reduced the incidence of TBE in Europe (Kunz et al.,
980). Two vaccines, manufactured in Austria and Ger-
any, are currently available in Europe. Both are chick
mbryo cell culture-derived CEEV preparations that are
nactivated with formalin and are delivered as a three-
ose series with adjuvant (Kunz et al., 1980; Heinz et al.,
980; Bock et al., 1990). Despite the success of these
accines, they have the disadvantages commonly asso-
iated with inactivated-virus vaccines such as the re-
uirement for large-scale production of a highly infec-
ious human pathogen, purification, the risk of incom-
lete inactivation of the virus, and the need to deliver
ultiple doses of the vaccines in adjuvant. Neither vac-
ine is licensed for use in the United States, so they are
ot available for U.S. travelers to TBE endemic regions.
For these reasons, we are interested in developing an
mproved TBE vaccine. We previously reported the eval-
ation of naked DNA vaccines for TBE in mice (Schmal-
ohn et al., 1997). We demonstrated that homologous and
eterologous protective immunity could be achieved by
ene gun inoculation of plasmid DNA expressing the
rM and E genes of either RSSEV or CEEV. In this study,
e evaluated the vaccines in rhesus macaques and
ompared the results with those obtained with the Aus-
rian commercial inactivated-virus vaccine.
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167TICK-BORNE ENCEPHALITIS DNA VACCINESRESULTS
ntigenicity of the DNA vaccines and the inactivated
EEV vaccine in rhesus macaques
Groups of four rhesus macaques were vaccinated on
ays 0, 30, and 70 by gene gun inoculation of DNA
accines expressing the prM and E genes of RSSEV,
EEV, or both DNA vaccines. Four control monkeys re-
eived the DNA vector plasmid with no insert. Monkeys
eceiving the individual RSSEV or CEEV vaccines and the
ontrol monkeys were given inoculations at four sites,
ach consisting of 2.5 mg of DNA coated onto 0.5 mg of
old beads. Monkeys that received both vaccines were
noculated at eight sites (four sites with each vaccine) at
he same dosage. Four additional monkeys were vacci-
ated at the same times by intramuscular injection of the
uman dose (0.5 ml, $1.0 mg of CEEV antigen) of a
ommercially available TBE vaccine (FSME-Immun In-
ect; Immuno-AG, Vienna, Austria). This vaccine consists
f formalin-inactivated CEEV formulated with adjuvant.
ntibody responses to RSSEV and CEEV were measured
y ELISA before each boost and 14 days after the final
accination. After the first vaccination, none of the mon-
FIG. 1. Direct IgG ELISAs were preformed with sera from monkeys
accine, the CEEV DNA vaccine, both DNA (RSSEV 1 CEEV) vaccines
ontaining no foreign gene insert (Control DNA). The cutoff of the as
eviations rounded up to the nearest tenth. The titer was equal to theeys in either the DNA or the commercial vaccine groups wisplayed detectable antibodies to either RSSEV or
EEV, and after the second vaccination, only low levels
ere detected (1:50–1:100) (data not shown). Two weeks
fter the third vaccination, all monkeys had ELISA titers
f $1:100 when screened on RSSEV antigen-coated
lates, and all except one had titers when screened on
EEV antigen-coated plates (Fig. 1).
Because ELISA was performed with crude infected-
ell lysate as antigen, it is likely that unequal concen-
rations of RSSEV and CEEV were used to coat the
LISA plates. Therefore, the titers to RSSEV and CEEV
annot be compared directly. Nevertheless, it is clear
hat the antibody responses obtained with the individ-
al RSSEV or CEEV vaccines were cross-reactive for
SSEV and CEEV antigen. All of the vaccinated mon-
eys had measurable antibody responses to RSSEV,
nd all except one (H7T, vaccinated with RSSEV DNA)
ad responses to CEEV. Compared with the groups of
onkeys that received only RSSEV or CEEV DNA,
onkeys that received both DNA vaccines had better
esponses to RSSEV but not to CEEV (Fig. 1). The
ighest ELISA Geometric mean titer (GMT) to CEEV
d 2 weeks after their third vaccination (day 84) with the RSSEV DNA
mmercial formalin-inactivated CEEV vaccine, or control plasmid DNA
as the mean OD value of negative control sera plus three standard
cal of the last dilution that was above or equal to the OD cutoff value.collecte
, the co
say w
reciproas obtained with the inactivated vaccine and the
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168 SCHMALJOHN ET AL.EEV DNA vaccine, with only a twofold difference
Fig. 1).
eutralizing antibody responses of vaccinated
onkeys
Neutralizing antibodies correlate with protective im-
unity to tick-borne flaviviruses, as demonstrated in
ice by passive transfer of neutralizing monoclonal an-
ibodies to M and E (Holzmann et al., 1997; Heinz et al.,
983). In humans, the administration of commercially
vailable immunoglobulin is recommended for prevent-
ng TBE when administered within 96 h after an infected
ick-bite (Immuno-AG, 1989). We measured the neutraliz-
ng antibody responses to CEEV in monkey serum sam-
les collected 2 weeks after the third vaccination (day
4). All except one of the vaccinated monkeys (H7T) had
laque reduction neutralization titers (PRNT80%) to CEEV
f $1280 (Fig. 2). Monkeys that received the RSSEV DNA
ad GMT of neutralizing antibodies to CEEV at least
ivefold lower than those that received the other vac-
ines. The GMT of sera from monkeys that received the
EEV DNA (alone or in combination with RSSEV DNA)
nd monkeys that received the inactivated vaccine were
imilar (Fig. 2).
FIG. 2. Neutralizing antibody responses to CEEV were measured for
4) with the RSSEV DNA vaccine, the CEEV DNA vaccine, both DNA (R
r control plasmid DNA containing no foreign gene insert (Control DNA
hen incubated at 37°C for 1 h and stored at 4°C overnight. The next
h, and then overlaid. Plaques were visualized by staining with neutral
f the highest dilution resulting in a 80% reduction of plaques comparTo assess the persistence of the neutralizing antibody gesponses, blood samples were collected 107 days after
he final vaccination (day 177) and again assayed by
RNT to CEEV. Reductions were observed in neutralizing
ntibody levels of individual monkeys from as little as
wofold to more than 30-fold. Nevertheless, PRNT80% ti-
ers for all monkeys except the one that originally had a
oor response remained at $160 (Fig. 2).
assive protection of mice by transfer of sera from
onkeys vaccinated with the RSSEV and CEEV
NA vaccines
Because neither RSSEV nor CEEV consistently causes
cute disease in monkeys, we were unable to evaluate
rotective efficacy of the DNA vaccines by direct chal-
enge of the primates. However, the known ability of
assively transferred immune globulin to protect humans
rom TBE (Immuno-AG 1989) suggests that protection
an be assayed by passive transfer of sera from the
mmunized monkeys to a susceptible animal. Conse-
uently, we assayed the ability of sera from the vacci-
ated monkeys to passively protect mice from challenge.
or these studies, we administered one additional
ooster with each vaccine. For the DNA vaccines, we
ested two different methods of boosting. One involved a
y serum samples collected 2 weeks after their third vaccination (day
CEEV) vaccines, the commercial formalin-inactivated CEEV vaccine,
ld dilutions of sera (1:20–1:640) were mixed with infectious CEEV and
samples were applied to monolayers of Vero E6 cells, adsorbed for
ays later. The neutralizing antibody titer was calculated as a reciprocal
a control of virus with no added antibody (PRNT80%).monke
SSEV 1
). Twofo
day, the
red 5 dene gun inoculation at a single site of 2.5 mg of DNA on
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169TICK-BORNE ENCEPHALITIS DNA VACCINES.5 mg of gold beads delivered at 400 psi. The second
ethod consisted of gene gun inoculations at four sites
or each DNA vaccine. Each site received 2.5 mg of DNA
oated onto 1 mg of gold. These injections were given at
50 psi with a gene gun hardware modification that
elivered the gold more evenly over the inoculation site.
e measured the neutralizing antibody responses of the
onkeys at 20 days after the booster inoculation. The
MT (PRNT80%) of all monkeys vaccinated with one
ooster was 1613 for RSSEV and 2032 for CEEV. For
onkeys that received DNA at four sites, the GMT was
032 and 4561 for RSSEV or CEEV, respectively. The
odified gun and protocol, therefore, did not noticeably
mprove the efficacy of boosting.
To assay protection, we transferred sera from mon-
eys vaccinated with both DNA vaccines or with the
ontrol plasmid to groups of mice by subcutaneous (s.c.)
njection. Mice received either 50 ml (approximately 2.5
l/kg) or 10 ml (approximately 0.5 ml/kg) of monkey sera
diluted in PBS to a final volume of 0.1 ml) 1 h before they
ere challenged with 100 LD50 of RSSEV or CEEV. If all of
he transferred serum appeared as circulating neutraliz-
ng antibodies in the mice, we calculated that the mice
eceiving 50 ml of serum should have PRNT titers ap-
roximately 20-fold less than those observed in the mon-
eys and that mice that received 10 ml should have PRNT
pproximately 100-fold less. However, analysis of blood
amples of two mice in each of the 50-ml transfer groups
T
Passive Transfer of 50 or 10 ml of Immune Mo
Monkey
DNA
vaccine
Gene
gun
boost
methoda
DNA
in
boost
(mg)
RSSEV
PRNT50%
monkey
serumb
CEEV
PRNT50%
monkey
serumb
T3C RSSE 1 CEE 1 site 5 10,240 10,240
V2G RSSE 1 CEE 1 site 5 1280 5120
E130 RSSE 1 CEE 4 sites 20 $20,480 $20,480
E127 RSSE 1 CEE 4 sites 20 10,240 $20,480
V9D Control 4 sites 10 ,20 ,20
a Two different gene gun boost methods were used. The one-site me
EEV DNA, which delivered 0.5 mg of gold coated with ;2.5 mg of DN
un. The four-site method consisted of four inoculations each of RSSE
er site at 550 psi, with the spinner hardware modification to the gene
b Sera from monkeys vaccinated with RSSEV and CEEV DNA, or with
nd assayed by plaque reduction neutralization tests. Titers are expres
50% (PRNT50%) compared with controls with no monkey serum.
c Monkey sera (50 ml or 10 ml) were diluted to a final volume of 0.1
d Two mice (designated a or b) from the 50-ml groups were exsangu
e Mice were challenged by intraperitoneal injection of 100 LD50 of C
NT 5 not titered.t 1 h after transfer (i.e., immediately before challenge) Cevealed that their actual neutralizing antibody titers
ere at least 10 times less than the predicted titers and
n some cases were undetectable (Table 1). Despite
hese low levels of circulating neutralizing antibodies, all
ive mice that received 50 ml of passively transferred
onkey sera remained healthy after challenge with
SSEV or CEEV. Although we did not measure circulating
evels of neutralizing antibodies in mice that received 10
l of monkey sera, we assumed that the actual titer was
lso less than the predicted titer and was likely to be
ndetectable by PRNT. Nevertheless, all of the mice in
ne of the groups remained healthy, and at least three
ice remained healthy in the other two groups (Table 1).
ll mice that died showed delayed times to death com-
ared with control mice (Fig. 3).
omparison of passive protection of mice by transfer
f sera from monkeys vaccinated with the individual
NA vaccines, both DNA vaccines, or the
nactivated-virus vaccine
We performed another passive transfer experiment in
ice to compare protection elicited by the individual
SSEV or CEEV DNA vaccines with that elicited by both
NA vaccines or the inactivated-virus vaccine. For this
tudy, groups of five mice each received 10 ml of serum
rom vaccinated monkeys or control monkeys by the s.c.
oute and were challenged 1 h later with 100 LD50 of
era to Mice and Challenge of Mice with CEEV
erum
nsferc
(ml)
RSSEV PRNT50%
of mice (a, b) 1
h after transferd
CEEV PRNT50%
of mice (a, b)
1 h after
transferd
Challenge of mice
with CEEVe
Morbidity Mortality
50 20, 40 40, 40 0/5 0/5
10 NT NT 0/5 0/5
50 ,20, 20 ,20, 20 0/5 0/5
10 NT NT 2/5 2/5
50 40, 40 40, 80 0/5 0/5
10 NT NT 1/5 1/5
50 ,20, ,20 20, 40 0/5 0/5
10 NT NT 1/5 1/5
50 ,20, ,20 ,20, ,20 5/5 5/5
10 NT NT 5/5 5/5
nsisted of one inoculation with RSSEV DNA and one inoculation with
site at 400 psi, without the spinner hardware modification of the gene
EEV DNA, which delivered 1 mg of gold coated with ;2.5 mg of DNA
trol plasmid were collected 20 days after the final booster vaccination
the highest reciprocal dilution that reduced the number of plaques by
BS and were inoculated s.c. into mice.
1 h after transfer, and PRNT50% was determined.
h after transfer of monkey sera.ABLE 1
nkey S
S
tra
thod co
A per
V or C
gun.
a con
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ml in P
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170 SCHMALJOHN ET AL.All mice that received sera from monkeys given both
he RSSEV and CEEV vaccines remained healthy after
SSEV challenge, and all except two remained healthy
fter CEEV challenge (Table 2). The two mice that died
ere recipients of sera from the monkey with the lowest
eutralizing antibody response to both RSSEV and CEEV
hat had received boosters at only one site with 5 mg of
NA (monkey V2G, Table 2). Similarly, all mice that re-
eived serum from monkeys that were vaccinated with
he formalin-inactivated vaccine remained healthy after
SSEV and CEEV challenge (Table 2).
Of the mice that received sera from monkeys vacci-
ated with the RSSEV DNA vaccine, all except one re-
ained healthy after RSSEV challenge. Sera from two of
he RSSEV DNA-vaccinated monkeys (KD9 and N6X, Ta-
le 2) were also able to passively protect all mice from
EEV challenge. However, mice that received sera from
he other two monkeys vaccinated with the RSSEV DNA
17075 and H7T, Table 2) were not completely protected
rom challenge with CEEV. As expected, mice that re-
eived monkey sera with the poorest neutralizing activity
o CEEV (i.e., serum from monkey H7T) showed the least
rotection from CEEV challenge (Table 2).
Sera from two monkeys that received the CEEV DNA
accine (90B025 and T4G, Table 2) passively protected
ll mice from both RSSEV and CEEV challenge. The
FIG. 3. Passive protection of mice with sera from monkeys immunize
ubcutaneously with 50 ml of serum (diluted to a final volume of 0.1 ml
EEV DNA vaccines or with sera from monkeys vaccinated with a DNA
ransfer, the mice were challenged by intraperitoneal injection of appro
ay of death was recorded.erum of another monkey (85765, Table 2) vaccinated Dith the CEEV DNA protected three of five mice from
SSEV challenge and four of five from CEEV challenge.
he final monkey that received the CEEV DNA vaccine
H9X) had very low levels of neutralizing antibodies to
SSEV and CEEV, and its serum failed to protect any
ice from morbidity after RSSEV or CEEV challenge
Table 2), although mice that died showed delayed time
o death compared with controls (data not shown).
DISCUSSION
Naked DNA vaccines to many viral pathogens have
een tested in animal models, but only a few have been
valuated in nonhuman primates (e.g., Fuller et al., 1995,
996, 1997; Lekutis et al., 1997; Lu et al., 1996; Lu, 1997;
asutomi et al., 1996) or in humans (e.g., Wang et al.,
998; MacGregor et al., 1998; Lu, 1997). The first clinical
tudy of a DNA vaccine delivered by gene gun particle
ombardment was recently concluded. The results dem-
nstrated that three doses of a hepatitis B virus DNA
accine elicited antibody levels known to correlate with
rotective immunity. These studies pave the way for
urther use of gene gun-delivered DNA vaccines for hu-
ans.
Gene gun inoculation differs from injection of DNA in
hat the particle bombardment method can deliver the
the RSSEV and CEEV DNA vaccines. Groups of 5 mice were injected
ndividual monkeys vaccinated with both the RSSEV DNA vaccine and
id with no foreign gene insert (control monkeys). One hour after serum
ly 100 LD50 of CEEV. Mice were observed daily for morbidity, and thed with
) from i
plasm
ximateNA directly into epidermal cells rather than into intra-
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171TICK-BORNE ENCEPHALITIS DNA VACCINESellular spaces. Consequently, only small amounts of
NA are required to elicit immune responses. Our pre-
ious studies with TBE DNA vaccines in mice demon-
trated that DNA expressing the prM and E genes of
SSEV or CEEV is able to induce neutralizing antibodies
nd confer cross-protective immunity to RSSEV and
EEV. Moreover, the protective immunity lasted for many
onths after vaccination (Schmaljohn et al., 1997).
To expand on those studies and as a prelude to pos-
ible clinical trials of our DNA vaccines, we evaluated
heir antigenicity and immunogenicity in monkeys. There
s no known satisfactory disease model for TBE in mon-
eys. Studies performed in bonnet monkeys (Macaca
adiata) demonstrated disease on infection with one
ember of the TBE virus complex, Kyasanur Forest dis-
T
Passive Transfer of 10 ml of Immune Monkey Ser
Monkey Vaccine
Gene
gun
boost
methoda
DNA in
boost
(mg)
Neutralizing
antibody responses
of monkeys to
RSSEVb
PRNT50% PRNT80
NA
17075 RSSE 1 site 2.5 10,240 2560
H7T RSSE 1 site 2.5 1280 ,640
KD9 RSSE 4 sites 10 5120 2560
N6X RSSE 4 sites 10 10,240 2560
B025 CEE 1 site 2.5 5120 ,640
5765 CEE 1 site 2.5 5120 640
T4G CEE 4 sites 10 $20,480 2560
H9X CEE 4 sites 10 ,640 ,640
T3C RSSE 1 CEE 1 site 5 10,240 2560
V2G RSSE 1 CEE 1 site 5 1280 10,240
E130 RSSE 1 CEE 4 sites 20 $20,480 5120
E127 RSSE 1 CEE 4 sites 20 10,240 2560
ormalin-inactivated
E128 Immuno 5120 2560
E121 Immuno 2560 640
E120 Immuno 5120 1280
E136 Immuno 10,240 5120
lasmid with no insert
V9D Control 4 sites 10
V3J Control 4 sites 10
E126 Control 1 site 2.5
PBS
a Two different gene gun methods were used for boosting the monke
NA vaccine for monkeys that received only RSSEV or CEEV. For monk
ach inoculation consisted of ;0.5 mg of gold coated with ;2.5 mg of
f the gene gun. The four-site method consisted of four gene gun ino
eceived both RSSEV and CEEV DNA. Each inoculation imparted app
elivered at 550 psi, with the spinner hardware modification to the gu
b Sera from monkeys vaccinated with RSSEV and CEEV DNA, or with
nd assayed by plaque reduction neutralization tests. Titers are expres
50% (PRNT50%) or 80% (PRNT80%) compared with controls with no mo
c Monkey sera (50 or 10 ml) were diluted to a final volume of 0.1 ml in
ice were challenged by intraperitoneal injection of 100 LD50 of RSSEase virus (Kenyon et al., 1992; Hambleton et al., 1983), (ut these monkeys did not develop disease consistently
hen infected with RSSEV or CEEV (R. Kenyon, unpub-
ished information). Similarly, only subclinical infections
f rhesus macaques (Macaca mulatta) were observed
fter intravenous inoculation of a Turkish strain of a TBE
omplex virus, and only about half of the animals in-
ected showed neurological disease after intranasal in-
culation (Hambleton et al., 1983). Rhesus macaques,
herefore, appear to be similar to humans in that only
ome infected individuals develop encephalitis or other
eurological symptoms. Although the monkeys were not
reliable disease model, they developed high levels of
eutralizing antibodies after infection and thus were use-
ul as an infection model for evaluating the safety and
fficacy of the Austrian inactivated-virus vaccine
ice and Challenge of Mice with RSSEV or CEEV
Neutralizing
tibody responses
of monkeys to
CEEVb
Passive protection in
mice: RSSEV
challengec
Passive protection in
mice: CEEV
challengec
NT50% PRNT80% Morbidity Mortality Morbidity Mortality
2560 1280 0/5 0/5 2/5 2/5
,640 ,640 1/5 1/5 5/5 4/5
5120 2560 0/5 0/5 0/5 0/5
5120 2560 0/5 0/5 0/5 0/5
0,240 5120 0/5 0/5 0/5 0/5
0,240 5120 2/5 2/5 1/5 1/5
0,480 10,240 0/5 0/5 0/5 0/5
2560 1280 5/5 4/5 5/5 5/5
0,240 2560 0/5 0/5 0/5 0/5
5120 2560 0/5 0/5 2/5 2/5
0,480 10,240 0/5 0/5 0/5 0/5
0,480 10,240 0/5 0/5 0/5 0/5
5120 2560 0/5 0/5 0/5 0/5
5120 2560 0/5 0/5 0/5 0/5
5120 2560 0/5 0/5 0/5 0/5
5120 2560 0/5 0/5 0/5 0/5
,20 ,20 5/5 5/5 5/5 5/5
,20 ,20 5/5 4/5 5/5 5/5
,20 ,20 5/5 4/5 5/5 5/5
20/20 18/20 10/10 9/10
e one-site method consisted of a single gene gun inoculation of each
t received both vaccines, one inoculation of each vaccine was given.
d was delivered at 400 psi without the spinner hardware modification
s of the individual vaccine, or four of each vaccine for monkeys that
ely 1 mg of gold coated with ;2.5 mg of DNA at each site and was
rol plasmid, were collected 20 days after the final booster vaccination
the highest reciprocal dilution that reduced the number of plaques by
rum.
nd were inoculated subcutaneously into mice. One hour after transfer,
EV.ABLE 2
a to M
an
% PR
1
1
$2
1
$2
$2
ys. Th
eys tha
DNA an
culation
roximat
n.
a cont
sed as
nkey se
PBS aHambleton et al., 1983).
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172 SCHMALJOHN ET AL.In our studies, we demonstrated that high levels of
eutralizing antibodies to RSSEV and CEEV could be
btained with either of the DNA vaccines and with a
ombination of the two vaccines. After three vaccina-
ions, neutralizing antibody titers to CEEV were high for
ll groups except those that received only the RSSEV
NA vaccine. It is noteworthy that the CEEV DNA vac-
ine elicited antibody titers as high as those of the
ommercial vaccine, even though the inactivated vaccine
as given at the human dose to animals that are much
maller than humans. Although we did not measure
eutralizing antibody levels to RSSEV after the initial
hree-dose series, we did measure them for serum sam-
les used for passive transfer studies, which were col-
ected 2 weeks after an additional (fourth) booster inoc-
lation. As a group, we found that the monkeys vacci-
ated with both DNA vaccines developed higher levels of
eutralizing antibodies to RSSEV (PRNT80% 5 GMT 4305)
han those that received only the RSSEV DNA vaccine
GMT 2153), the CEEV DNA vaccine (GMT 640), or the
ommercial inactivated CEEV vaccine (GMT 1810). Like-
ise, as a group, monkeys vaccinated with both DNA
accines had higher levels of neutralizing antibodies to
EEV (PRNT80% 5 GMT 5120) than did monkeys vacci-
ated with the RSSEV DNA vaccine (GMT 1280), the
EEV DNA vaccine (GMT 4305), or the commercial inac-
ivated-virus vaccine (GMT 1280). For the DNA vaccines,
e do not know whether the higher titers reflect a broad-
ned immune response elicited by the combination of
he two vaccines compared with the individual vaccine or
f they reflect the influence of twice as much DNA dis-
ributed over twice as many sites on the skin per vacci-
ation. Future studies aimed at determining optimal dos-
ges of the DNA vaccines may address this question.
egardless of the reason, the combination of both DNA
accines generated neutralizing antibody responses
uantitatively equal to those elicited by a vaccine known
o protect from TBE. In addition, the antibody titers per-
isted for at least 15 weeks after vaccination at levels
ell above what we demonstrated to offer complete
rotection in mice.
Not only were antibody titers similar in monkeys vac-
inated with both DNA vaccines or with the inactivated-
irus vaccine, but also the protective immunity, as mea-
ured by passive transfer of serum from monkeys to
ice, also appeared to be very similar. That is, all 20
ice in groups that received sera from monkeys vacci-
ated with both DNA vaccines or in groups that received
era from monkeys vaccinated with the inactivated-virus
accine remained healthy after RSSEV challenge. Al-
hough 2 of the 20 mice given sera from monkeys vac-
inated with both DNA vaccines did not survive chal-
enge with CEEV, whereas all 20 that received sera from
onkeys vaccinated with the inactivated-virus vaccine
emained healthy, this difference was not found to be
tatistically significant. Of course, it is possible that the Inactivated-virus vaccine elicits a broader and more ef-
ective immune response because of the additional an-
igens in the vaccine; however, further studies are re-
uired to address that possibility.
In summary, these studies offer encouragement for the
se of DNA vaccines for TBE in humans. Additional
tudies will be required to determine optimal parameters
f dosage and frequency of vaccination required to elicit
rotective immunity in humans.
MATERIALS AND METHODS
iruses, cells, and media
The origins of the RSSEV, strain Sofjin, and CEEV,
train Hypr, were described previously (Schmaljohn et
l., 1997; Calisher 1988). RSSEV and CEEV were propa-
ated and assayed in Vero E6 cells maintained in Eagle’s
inimal essential medium supplemented with 10% FBS
nd antibiotics as described previously (Schmaljohn et
l., 1997). All studies with infectious RSSEV or CEEV
ere conducted in a biosafety level 4 laboratory.
reparation of gene gun cartridges
Construction of the DNA vaccines expressing the prM
nd E genes of RSSEV and CEEV were described previ-
usly (Schmaljohn et al., 1997). Plasmid DNA was pre-
ipitated onto the outside surface of gold beads (approx-
mately 2 mm in diameter) as described earlier (Eisen-
raun et al., 1993). The DNA-coated gold particles were
ried on the inside walls of Tefzel tubing, which was then
ut into 0.5-inch sections to make cartridges for the gene
un (Pertmer et al., 1995). Final amounts of DNA in each
artridge was measured by fluorometric assays of eluted
NA or estimated by gel electrophoresis and compari-
on with ethidium bromide-stained standards.
onkey vaccinations
Monkeys were anesthetized with Telazol at a dosage
f 3–6 mg/kg body wt. before handling, vaccination, and
hlebotomy. The PowderJect-XR gene delivery device (D.
cCabe, inventor; Agracetus, Inc., assignee; PCT patent
O 95/19799, July 27, 1995) was used to achieve intra-
ellular inoculation of epidermal cells. Twenty adult rhe-
us macaques (Macaca mulatta) were randomized into
ive groups of four animals each. Groups 1–4 received
aked DNA vaccines for RSSEV, CEEV, RSSEV and CEEV,
r plasmid with no insert, respectively. DNA vaccinations
onsisted of gene gun inoculation of approximately 2.5
g of DNA coated onto 0.5 mg of gold beads delivered to
he lower abdomen at each of four sites (for the monkeys
eceiving the individual DNA vaccines) or eight sites (for
he monkeys receiving both DNA vaccines) with a pres-
ure setting of 400 psi. Group 5 monkeys received a
uropean commercial vaccine for TBE (FSME-Immunnject; Immuno AG). This vaccine is a suspension of
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173TICK-BORNE ENCEPHALITIS DNA VACCINESurified CEEV that is propagated in chicken embryo
ells, inactivated with formalin, and formulated with alu-
inum hydroxide adjuvant. Monkeys received the vac-
ine at the recommended human dose of 0.5 ml intra-
uscularly in the upper arm using the preloaded needle
nd syringe that accompany the vaccine. All vaccines
ere administered on days 0, 30, and 70. Blood samples
ere collected before each vaccination and at days 84
nd 177. Samples from days 0, 30, 70, and 84 were
xamined by ELISA, and samples from days 84 and 177
ere assayed by PRNT. At day 177, a booster inoculation
f each vaccine was administered. For the commercial
accine, the same dosage was used as in earlier vacci-
ations. For the DNA vaccines, two monkeys in each
roup received approximately 2.5 mg of the RSSEV vac-
ine, the CEEV vaccine, or the control plasmid at a single
ite on the lower abdomen (two sites for those that
eceived both the RSSEV and CEEV vaccines). The other
wo monkeys in each group received approximately 2.5
g of gold delivered to each of four sites (eight sites for
hose that received both vaccines). For these monkeys, a
odified gene gun protocol was used in which a hard-
are modification of the gun (“spinner” insert) was used
hat was intended to result in more even distribution of
he gold over the inoculation site. In addition, the pres-
ure was increased from 400 to 550 psi and the amount
f gold was increased from 0.5 to 1 mg/dose. Blood
amples were collected 20 days after the vaccination
nd assayed by PRNT.
erological assays
Direct IgG ELISA was performed as described earlier
Schmaljohn et al., 1997). The cutoff of the assay was the
ean OD value of negative control sera plus three stan-
ard deviations rounded up to the nearest tenth. An OD
alue was considered positive if it was greater than or
qual to this value. The titer was equal to the reciprocal
f the last dilution that was above or equal to the OD
utoff value. PRNT assays were performed as previously
escribed (Schmaljohn et al., 1997).
assive transfer of immune sera to mice and
hallenge with RSSEV or CEEV
Monkey sera were diluted in sterile PBS to deliver 50
l (;2.5 ml/kg) or 10 ml (;0.5 ml/kg) in a volume of 0.1
l. Each diluted serum was injected subcutaneously into
- to 8-week-old BALB/c mice. The blood volume of a
ALB/c mouse is approximately 5.85 ml/100 g. The 6- to
-week-old female BALB/c mice in our experiments
eighed approximately 20 g. Therefore, each mouse had
blood volume of approximately 1.17 ml. Passive transfer
f 10 or 50 ml of monkey sera to a BALB/c mouse
esulted in a calculated dilution of approximately 1:117 or
:23, respectively. One hour after transfer, the mice were
hallenged by intraperitoneal inoculation of approxi-ately 50 PFU of suckling mouse brain-passaged RSSEV
r CEEV, a dose previously determined to be approxi-
ately 100 LD50 for BALB/c mice. Mice were observed
aily for 25 days for signs of illness and for death.
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